Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Novo Nordisk (NVO) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to update the Ozempic (once-weekly ...

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...

Orforglipron is an oral drug from Eli Lilly that’s in trial stage. The New York Times reports that in a trial of over 500 ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

BTTV brings you a new market show - 'Daily Calls,' where you can gain invaluable insights and clarity on your market queries through our live sessions featuring expert analysts. Whether you're ...